The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The management of patients with activated PI3K delta syndrome
V. Koneti Rao, MD, FRCPA, National Institute of Allergy and Infectious Diseases, Bethesda, MD, talks on the current management of patients with activated PI3K delta syndrome (APDS/PASLI). This includes supportive care, immunoglobulin replacement therapy, and mTOR inhibitors such as sirolimus or everolimus. The efficacy of leniolisib, a delta PI3K inhibitor, is also discussed. Moreover, Dr Rao discusses the challenges and risks of bone marrow transplantation for the treatment of this rare disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
